In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ablynx nets $214mm in Nasdaq IPO

Executive Summary

Euronext Brussels-traded Ablynx NV (therapeutic protein platform known as Nanobodies) netted $214mm through an initial public offering on the Nasdaq exchange of 13.1mm ordinary shares (including the overallotment) in the form of American Depositary Shares (ADSs) with each ADS representing the right to receive one ordinary share at $17.50 apiece. The company originally planned to offer 9.2mm ADSs at a price between $17.90-19.08 per ADS.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies